Quantitative Mass Spectrometry Identifies Drug Targets in Cancer Stem Cell-containing Side Population

Overview

Journal Stem Cells

Publisher Oxford University Press

Specialties Cell Biology
Reproductive Medicine

Date 2008 Sep 20

PMID 18802034

Citations 20

Authors

Sebastian C J Steiniger

Judith A Coppinger

Jorg A Kruger

John Yates 3rd

Kim D Janda

Affiliations

Soon will be listed here.

Abstract

A multifaceted approach is presented as a general strategy to identify new drug targets in a breast cancer stem cell-containing side population. The approach we have utilized combines side population cell sorting and stable isotope labeling by amino acids in cell culture with mass spectrometry to compare and identify proteins with differential expression profiles between side population cells, know to be enriched in cancer stem cells, and nonside population cells, which are depleted in cancer stem cells, for two breast cancer cell lines, MCF7 and MDA-MB231. Almost 900 proteins were quantified, and several important proteins in cell cycle control and differentiation were found to be upregulated in the cancer stem cell-containing side population. Most interestingly, a splice isoform of pyruvate kinase M2 as well as peroxiredoxin 6 were found to be downregulated. The differential levels of three of these proteins, thymosin beta4 (TB4), proliferation-associated protein 2G4, and SIAH-interacting protein, were validated using Western blot. Furthermore, functional validation provided clear evidence that elevated TB4 expression contributes to drug resistance in the stem cell population. Small interfering RNA silencing of TB4 led to a loss of chemoresistance in two separate breast cancer populations. These proteins likely contribute to resistance in the cancer stem cell-containing side population, and their altered expression in a tumor causes clinical resistance to chemotherapy. The ability to perform quantitative mass spectrometry has enabled the identification of a series of proteins that could serve as future therapeutic targets.

Citing Articles

New findings on the action of hypericin in hypoxic cancer cells with a focus on the modulation of side population cells.

Bulkova V, Vargova J, Babincak M, Jendzelovsky R, Zdrahal Z, Roudnicky P Biomed Pharmacother. 2023; 163:114829.

PMID: 37146419 PMC: 10227191. DOI: 10.1016/j.biopha.2023.114829.

Breast Cancer Stem Cells: Biomarkers, Identification and Isolation Methods, Regulating Mechanisms, Cellular Origin, and Beyond.

Zhang X, Powell K, Li L Cancers (Basel). 2020; 12(12).

PMID: 33327542 PMC: 7765014. DOI: 10.3390/cancers12123765.

Proteins and Molecular Pathways Relevant for the Malignant Properties of Tumor-Initiating Pancreatic Cancer Cells.

Samonig L, Loipetzberger A, Blochl C, Rurik M, Kohlbacher O, Aberger F Cells. 2020; 9(6).

PMID: 32503348 PMC: 7349116. DOI: 10.3390/cells9061397.

Metformin Suppresses Self-Renewal Ability and Tumorigenicity of Osteosarcoma Stem Cells via Reactive Oxygen Species-Mediated Apoptosis and Autophagy.

Zhao B, Luo J, Wang Y, Zhou L, Che J, Wang F Oxid Med Cell Longev. 2019; 2019:9290728.

PMID: 31827709 PMC: 6885828. DOI: 10.1155/2019/9290728.

Cancer stem cells as a potential therapeutic target in breast cancer.

Zhang M, Li Z, Zhang X, Chang Y Stem Cell Investig. 2016; 1:14.

PMID: 27358860 PMC: 4923512. DOI: 10.3978/j.issn.2306-9759.2014.06.01.

References

Goodell M, Brose K, Paradis G, Conner A, Mulligan R . Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996; 183(4):1797-806. PMC: 2192511. DOI: 10.1084/jem.183.4.1797. View

Hall A . Differential expression of thymosin genes in human tumors and in the developing human kidney. Int J Cancer. 1991; 48(5):672-7. DOI: 10.1002/ijc.2910480507. View

Bonnet D, Dick J . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7):730-7. DOI: 10.1038/nm0797-730. View

Santelli G, Califano D, Chiappetta G, Vento M, Bartoli P, Zullo F . Thymosin beta-10 gene overexpression is a general event in human carcinogenesis. Am J Pathol. 1999; 155(3):799-804. PMC: 1866886. DOI: 10.1016/s0002-9440(10)65178-4. View

Bruce W, VAN DER GAAG H . A QUANTITATIVE ASSAY FOR THE NUMBER OF MURINE LYMPHOMA CELLS CAPABLE OF PROLIFERATION IN VIVO. Nature. 1963; 199:79-80. DOI: 10.1038/199079a0. View

Zhou X, Chang Y, Oyama T, McGuire M, Brown K . Cell-specific delivery of a chemotherapeutic to lung cancer cells. J Am Chem Soc. 2004; 126(48):15656-7. DOI: 10.1021/ja0446496. View

Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D . Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005; 65(13):5506-11. DOI: 10.1158/0008-5472.CAN-05-0626. View

Oh S, Song J, Gil J, Kim J, Yeom Y, Moon E . ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance. Exp Cell Res. 2006; 312(9):1651-7. DOI: 10.1016/j.yexcr.2006.01.030. View

He W, Dorn D, Erdjument-Bromage H, Tempst P, Moore M, Massague J . Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell. 2006; 125(5):929-41. DOI: 10.1016/j.cell.2006.03.045. View

10.

Huff C, Matsui W, Smith B, Jones R . Strategies to eliminate cancer stem cells: clinical implications. Eur J Cancer. 2006; 42(9):1293-7. DOI: 10.1016/j.ejca.2006.01.045. View

11.

Kruger J, Kaplan C, Luo Y, Zhou H, Markowitz D, Xiang R . Characterization of stem cell-like cancer cells in immune-competent mice. Blood. 2006; 108(12):3906-12. DOI: 10.1182/blood-2006-05-024687. View

12.

Mann M . Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol. 2006; 7(12):952-8. DOI: 10.1038/nrm2067. View

13.

Elias J, Gygi S . Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods. 2007; 4(3):207-14. DOI: 10.1038/nmeth1019. View

14.

Shipitsin M, Campbell L, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J . Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007; 11(3):259-73. DOI: 10.1016/j.ccr.2007.01.013. View

15.

Venable J, Wohlschlegel J, McClatchy D, Park S, Yates 3rd J . Relative quantification of stable isotope labeled peptides using a linear ion trap-Orbitrap hybrid mass spectrometer. Anal Chem. 2007; 79(8):3056-64. PMC: 3586273. DOI: 10.1021/ac062054i. View

16.

Piscaglia A, Shupe T, Gasbarrini A, Petersen B . Microarray RNA/DNA in different stem cell lines. Curr Pharm Biotechnol. 2007; 8(3):167-75. DOI: 10.2174/138920107780906478. View

17.

Kelly P, Dakic A, Adams J, Nutt S, Strasser A . Tumor growth need not be driven by rare cancer stem cells. Science. 2007; 317(5836):337. DOI: 10.1126/science.1142596. View

18.

Stingl J, Caldas C . Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer. 2007; 7(10):791-9. DOI: 10.1038/nrc2212. View

19.

Everley P, Gartner C, Haas W, Saghatelian A, Elias J, Cravatt B . Assessing enzyme activities using stable isotope labeling and mass spectrometry. Mol Cell Proteomics. 2007; 6(10):1771-7. DOI: 10.1074/mcp.M700057-MCP200. View

20.

Christgen M, Ballmaier M, Bruchhardt H, von Wasielewski R, Kreipe H, Lehmann U . Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line. Mol Cell Biochem. 2007; 306(1-2):201-12. DOI: 10.1007/s11010-007-9570-y. View